Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivus Inc VVUSQ

Healthcare Biotechnology
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic... see more

Recent & Breaking News (OTCPK:VVUSQ)

VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies

PR Newswire April 16, 2013

First Manhattan Co. Issues Statement on Expected REMS Modification for Qsymia

Business Wire April 10, 2013

Free Research Reports on CRL, HL, TSLA and VVUS Issued by the Paragon Report

Marketwired April 5, 2013

Morning Research on Sanofi, Keryx Biopharma, VIVUS, and Array BioPharma

PR Newswire March 27, 2013

VIVUS Announces $110 Million Synthetic Capped Royalty Financing

Globe Newswire March 26, 2013

VIVUS Confirms Receipt of Notice of Nomination From First Manhattan Co.

Troy Schwensen March 8, 2013

VIVUS Launches Mobile App to Help Patients Lose Weight

PR Newswire March 7, 2013

Anti-Obesity Drug Market a Major Focus as Obesity in the U.S. Adds More to Healthcare Costs Than Smoking

Marketwired March 6, 2013

VIVUS Announces New Qsymia Offer

PR Newswire March 5, 2013

VIVUS to Present at Three Investor Conferences in March 2013

Troy Schwensen March 4, 2013

Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies

PR Newswire February 26, 2013

VIVUS Reports 2012 Fourth Quarter and Full-Year Financial Results

Troy Schwensen February 25, 2013

Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High

Marketwired February 25, 2013

Free Research Reports on AIG, AVG, FRO and VVUS Issued by the Bedford Report

Marketwired February 25, 2013

VIVUS Receives Decision Regarding Qsiva Appeal

Troy Schwensen February 21, 2013

Free Research Report on USG Corp., Dendreon Corp., Alpha Natural Resources, Inc., VIVUS, Inc. and HSBC Holdings Plc

Marketwired February 15, 2013

Did You Miss VVUS, XRX, ARR and GNW

Marketwired February 12, 2013

VIVUS to Present at Three Investor Conferences in February 2013

Troy Schwensen February 8, 2013

Study Concludes That Weight Loss With Qsymia(tm) Significantly Improves Multiple Cardiovascular Disease Risk Factors

PR Newswire February 1, 2013

Free Research Reports on AVEO, CLSN, PATH and VVUS Issued by the Bedford Report

Marketwired January 18, 2013